默沙东67亿美元收购拓臻生物,缘何选择押注新一代白血病疗法?

21世纪经济报道
Mar 26

21世纪经济报道记者季媛媛  3月25日,制药巨头默沙东与生物科技公司Terns Pharmaceuticals(拓臻生物)联合宣布,双方已达成最终收购协议。默沙东将通过其子公司以每股53.00美元现金收购Terns所有流通股,总股权价值约67亿美元。扣除Terns账面持有的现金后,交易净值约为57亿美元。  继2025年7月,以约100亿美元收购英国Verona Pharma,获得其慢阻肺药物...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10